Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has received approval from the Australian Human Research Ethics Committee (HREC) to expand the company’s global clinical trial to Australia, to study SBP-101 in combination with Gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, which is referred to as the ASPIRE trial. The ASPIRE trial is designed as a randomized double-blind placebo-controlled trial, with a primary endpoint of overall survival.